Compare Johnson & Johnson (JNJ) vs Petróleo Brasileiro SA (PBR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Petróleo Brasileiro SA — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while Petróleo Brasileiro SA trades at $25.36 (market cap $151.94B). The key difference: Johnson & Johnson is far larger — about 4.1× Petróleo Brasileiro SA's market cap, and Petróleo Brasileiro SA pays the higher dividend (6.79%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Petróleo Brasileiro SA for 25 Days on average.
| JNJ | PBR | |
|---|---|---|
Market Cap | $618.09B | $151.94B |
Volume | 6,050,983 | 30,240,092 |
Sector | Health | Energy |
52-Week High | $278.43 | $24.69 |
52-Week Low | $186.00 | $11.54 |
Typical Hold Time | 129 Days | 25 Days |
Enterprise Value | $646.37B | $212.36B |
Dividend Yield | 2.09% | 6.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
Petrobras (PBR) trades at $25.41, up 5.92% in 24 hours, reflecting strong momentum. The stock shows robust fundamentals with a P/E of 6.24 and net income margin of 24.52%, supported by recent earnings beats. Technical indicators signal a bullish trend, though RSI levels suggest potential overbought conditions. Positive news includes a new oil discovery off Amapa and a 22-year LNG deal with Cheniere Energy, highlighting growth prospects.
The outlook for PBR is favorable due to solid profitability, expansion projects, and analyst consensus leaning buy. Key risks involve political interference in Brazil, volatile oil prices, and high debt levels. Investors should weigh strong cash flows against geopolitical and commodity cycle exposures for balanced decision-making.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →
